Easy and Efficient Protocols for Working with Recombinant Vaccinia Virus MVA

Kremer, Melanie; Volz, Asisa; Kreijtz, Joost H. C. M.; Fux, Robert; Lehmann, Michael H.; Sutter, Gerd

doi:10.1007/978-1-61779-876-4_4

Cited by 71 publications

(101 citation statements)

References 18 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…MVA (cloned isolate F6), recombinant MVA expressing the green fluorescent protein (MVA-GFP) under the control of the VACV P7.5 early/late promoter (20), and VACV strain Western Reserve (WR), which was originally provided by Bernard Moss (NIH, Bethesda, MD), were propagated in chicken embryo fibroblasts (CEF). Virus stocks were purified by sucrose density centrifugation and titrated using standard methodology (21). All virus stocks were checked for mycoplasma contamination prior to use.…”

Section: Methodsmentioning

confidence: 99%

Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara

Price

Luckow

Torres-Domínguez

et al. 2014

J Virol

Self Cite

View full text Add to dashboard Cite

Modified vaccinia virus Ankara (MVA) serves as a versatile platform in vaccine development. This highly attenuated orthopoxvirus, which cannot replicate in mammalian cells, triggers strong innate immune responses, including cell migration. Previously, we have shown that induction of chemokine (C-C motif) ligand 2 (CCL2) by MVA is necessary for the recruitment of monocytes and T cells, but not neutrophils, to the lung. Here, we identified neutrophil-attracting chemokines produced by MVA-infected primary murine lung fibroblasts and murine bone marrow-derived macrophages. We demonstrate that MVA, but not vaccinia virus (VACV) strain WR, induces chemokine expression, which is independent of Toll-like receptor 2 (TLR2) signaling. Additionally, we show that both chemokine (C-C motif) receptor 1 (CCR1) and chemokine (C-X-C motif) receptor 2 (CXCR2) are involved in MVA-induced neutrophil chemotaxis in vitro. Finally, intranasal infection of Ccr1 ؊/؊ mice with MVA, as well as application of the CCR1 antagonist J-113863, revealed a role for CCR1 in leukocyte recruitment, including neutrophils, into the lung.

show abstract

Section: Methodsmentioning

confidence: 99%

Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara

Price

Luckow

Torres-Domínguez

et al. 2014

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Established standard protocols allow rapidly obtaining recombinant MVA (rMVA) which are suitable for clinical evaluation (for review see [146]). This can be done by infection of CEF with fully characterized non-recombinant MVA seed virus and subsequent transfection of vector plasmid DNA containing the target gene of interest.…”

Section: Future Perspectivesmentioning

confidence: 99%

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

Altenburg

Kreijtz

Vries

et al. 2014

Viruses

Self Cite

110

102

View full text Add to dashboard Cite

Respiratory viruses infections caused by influenza viruses, human parainfluenza virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for public health. Currently, there are no licensed vaccines available for hPIV, RSV and coronaviruses, and the available seasonal influenza vaccines have considerable limitations. With regard to pandemic preparedness, it is important that procedures are in place to respond rapidly and produce tailor made vaccines against these respiratory viruses on short notice. Moreover, especially for influenza there is great need for the development of a universal vaccine that induces broad protective immunity against influenza viruses of various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform. MVA can encode one or more foreign antigens and thus functions as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular immune responses. However, there are some practical and regulatory issues that need to be addressed in order to develop MVA-based vaccines on short notice at the verge of a pandemic. In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses.

show abstract

“…Recombinant viral vector vaccines offer this feature in addition to several further advantages, including well-characterized safety profiles, efficient replication in cultivation systems and potent induction of a broad range of host immune mechanisms373839. The lentogenic Newcastle disease virus (NDV) Clone 30 and the heavily attenuated poxvirus strain modified vacciniavirus Ankara (MVA) are well-established vector platforms4041. NDV Clone 30 is derived from a commercial NDV live vaccine which is widely used in poultry flocks40.…”

mentioning

confidence: 99%

Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canaries

Olbert

Römer-Oberdörfer

Herden

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Avian bornaviruses are causative agents of proventricular dilatation disease (PDD), an often fatal disease of parrots and related species (order Psittaciformes) which is widely distributed in captive psittacine populations and may affect endangered species. Here, we established a vaccination strategy employing two different well described viral vectors, namely recombinant Newcastle disease virus (NDV) and modified vaccinia virus Ankara (MVA) that were engineered to express the phosphoprotein and nucleoprotein genes of two avian bornaviruses, parrot bornavirus 4 (PaBV-4) and canary bornavirus 2 (CnBV-2). When combined in a heterologous prime/boost vaccination regime, NDV and MVA vaccine viruses established self-limiting infections and induced a bornavirus-specific humoral immune response in cockatiels (Nymphicus hollandicus) and common canaries (Serinus canaria forma domestica). After challenge infection with a homologous bornavirus, shedding of bornavirus RNA and viral loads in tissue samples were significantly reduced in immunized birds, indicating that vaccination markedly delayed the course of infection. However, cockatiels still developed signs of PDD if the vaccine failed to prevent viral persistence. Our work demonstrates that avian bornavirus infections can be repressed by vaccine-induced immunity. It represents a first crucial step towards a protective vaccination strategy to combat PDD in psittacine birds.

show abstract

Easy and Efficient Protocols for Working with Recombinant Vaccinia Virus MVA

Cited by 71 publications

References 18 publications

Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara

Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canaries

Contact Info

Product

Resources

About